

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

PARRY ROMANI DECONCINI & SYMMS

2. Address:

517 C STREET, NE, WASHINGTON, DC 20002

3. Principal place of business (if different from line 2):

4. Contact Name: MICHELLE MAGOON

Telephone: 2025474000

E-mail (optional): mmagoon@lobbycongress.com

Senate ID #: 30792-2206

House ID #:

7. Client Name: Self

NOVARTIS CORP

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): 100,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

Funds for domestic vaccine supply, Centers for Disease Control, National Institutes of Health and Vaccine Injury Compensation Fund, H.R. 3010: Making appropriations for the Departments of Labor, Health and Human Services, and Education, and Related Agencies for the fiscal year ending September 30, 2006, and for other purposes. Lobbied for sufficient funding of the CDC and NIH.

17. House(s) of Congress and Federal agencies contacted:

Centers For Disease Control & Prevention
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
Natl Institutes of Health (NIH)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD
Covered Official Position (if applicable): N/A
Name: DECONCINI, DENNIS
Covered Official Position (if applicable): N/A
Name: HADDOW, JOHN
Covered Official Position (if applicable): N/A
Name: ROCK, JAMES
Covered Official Position (if applicable): N/A
Name: ROMANI, ROMANO
Covered Official Position (if applicable): N/A
Name: STROM, THADDEUS
Covered Official Position (if applicable): N/A
Name: SYMMS, STEVE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R. 2791: To amend title 35, United States Code, with respect to patent fees, and for other purposes. Lobbied for reasonable patent fees and to protect intellectual property rights. H.R. 357, S. 167: To provide for the protection of intellectual property rights, and for other purposes. Lobbied to protect the Biopharmaceutical industry's intellectual property rights.

H.R. 2795: To amend title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect the Biopharmaceutical industry's intellectual property rights.

S. 167: a bill to provide for the protection of intellectual property rights, and for other purposes. Lobbied to protect the Biopharmaceutical industry's intellectual property rights.

H.R. 2795: To amend title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect intellectual property rights.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD
Covered Official Position (if applicable): N/A
Name: DECONCINI, DENNIS
Covered Official Position (if applicable): N/A
Name: HADDOW, JOHN
Covered Official Position (if applicable): N/A
Name: ROCK, JAMES
Covered Official Position (if applicable): N/A
Name: ROMANI, ROMANO
Covered Official Position (if applicable): N/A
Name: STROM, THADDEUS
Covered Official Position (if applicable): N/A
Name: SYMMS, STEVE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R.650: To establish reasonable legal reforms that will facilitate the manufacture of vital, life-saving vaccines, and for other purposes. Lobbied for the interests of the vaccine industry.
Public Health Service Act with respect to the National Vaccine Injury Compensation Program. Lobbied for the interests of the vaccine industry.
H.R.1297: To amend the
H.R.840, S.399: A bill to amend the Federal Food, Drug and Cosmetic Act with respect to the sale of prescription drugs through the internet, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products.
H.R.1808, S.334: To amend the Federal Food, Drug, and Cosmetic Act to create a uniform certification standard for Internet pharmacies and to prohibit Internet pharmacies from engaging in certain advertising activities, to prohibit the use of certain bank instruments for purchases associated with illegal Internet pharmacies, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products.
S.1873: A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines.
S.1527: Vaccine Access and Supply Act, lobbied for provisions to strengthen the domestic vaccine industry.
H.R.3052,
H.R.3970: Bioterror and Pandemic Preparedness Protection Act, lobbied in support of provisions to assure domestic pandemic preparedness.
S.1821: Pandemic Preparedness and Response Act, lobbied in support of provisions to assure domestic pandemic preparedness.
S.1828:
Influenza Vaccine Security Act of 2005, lobbied in support of provisions to assure as strong domestic vaccine industry.
S.1912: Global Network for Avian Influenza Surveillance Act, lobbied in support of domestic pandemic preparedness.
S.375: Flu Protection Act of 2005, lobbied in support of domestic influenza provisions to stabilize production and supply.
S.969: Attacking Viral Influenza Across Nations Act of 2005, lobbied in support of influenza provisions.
General matters related to vaccine industry stability, pandemic preparedness, avian influenza.
S.969,H.R.3369: A bill to amend the Public Health Service Act with respect to preparation for an influenza pandemic, including an avian influenza pandemic, and for other purposes. Lobbied for the interests of the vaccine industry.

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD
Covered Official Position (if applicable): N/A
Name: DECONCINI, DENNIS
Covered Official Position (if applicable): N/A
Name: HADDOW, JOHN
Covered Official Position (if applicable): N/A
Name: ROCK, JAMES
Covered Official Position (if applicable): N/A
Name: ROMANI, ROMANO
Covered Official Position (if applicable): N/A
Name: STROM, THADDEUS
Covered Official Position (if applicable): N/A
Name: SYMMS, STEVE
Covered Official Position (if applicable): N/A

Registrant Name: PARRY ROMANI DECONCINI & SYMMS Client Name: NOVARTIS CORP

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HOM (one per page)

16. Specific lobbying issues:

S. 975: A bill to provide incentives to increase research by private sector entities to develop medical counter measures to prevent, detect, identify, contain, and treat illnesses, including those associated with biological, chemical, nuclear, or radiological weapons attack or an infectious disease outbreak, and for pandemic preparedness provisions.

"S. 1873: A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines.

H.R. 1815, S. 1042:

National Defense Authorizations Act for Fiscal Year 2006. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines.

H.R. 2601: To

authorize appropriations for the Department of State for Fiscal Years 2006 and 2007. Lobbied for sufficient funding for bioterrorist medical counter measures.

S. 3: A

bill to strengthen and protect America in the war on terror. Lobbied for incentives to manufacture biomedical counter measures.

17. House(s) of Congress and Federal agencies contacted:

Centers For Disease Control & Prevention
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD

Covered Official Position (if applicable): N/A

Name: DECONCINI, DENNIS

Covered Official Position (if applicable): N/A

Name: HADDOW, JOHN

Covered Official Position (if applicable): N/A

Name: ROCK, JAMES

Covered Official Position (if applicable): N/A

Name: ROMANI, ROMANO

Covered Official Position (if applicable): N/A

Name: STROM, THADDEUS

Covered Official Position (if applicable): N/A

Name: SYMMS, STEVE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 05, 2007

Printed Name and Title: ROMANO ROMANI, PRESIDENT -